Clik here to view.
G-TACとエムスリー（ソニー関連会社）がCancerIntercept™やBRCATrue®などの遺伝子検査サービスの日本での提供に向けパスウェイ・ゲノ...
東京 （ビジネスワイヤ） — G-TAC Co., Ltd.とエムスリー（ソニーの関連会社）はパスウェイ・ゲノミクスとの戦略的事業提携により、日本における医師2万人以上から成るG-TACのゲノミクスネットワークを通じ、CancerIntercept™、BRCATrue®、PathwayFit®、SkinFit™、その他の遺伝子検査を含む14種類の検査サービスを提供すると発表しました。...
View ArticleClik here to view.
Seattle Genetics与武田宣布，《血液》杂志发表ADCETRIS® (Brentuximab...
华盛顿州博瑟尔、马萨诸塞州剑桥和日本大阪 (美国商业资讯) — Seattle Genetics, Inc. (NASDAQ:SGEN)与武田药品工业株式会社(TSE:4502)今天宣布，《血液》杂志发表ADCETRIS (brentuximab...
View ArticleClik here to view.
Starpharma签署VivaGel®避孕套在中国的授权
澳大利亚墨尔本 (美国商业资讯) — 澳大利亚生物科技公司Starpharma Holdings Ltd (ASX:SPL)(OTCQX:SPHRY) 七月二十一日宣布，与沈阳天地乳胶有限公司（天地公司）签署排他性授权和供货协议，面向中国避孕套市场的政府细分市场生产和销售VivaGel®避孕套。该协议之前，Starpharma于2015年12月与天地公司签署了谅解备忘录。...
View ArticleClik here to view.
CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the Taiwan Food and Drug Administration (TFDA) has...
View ArticleClik here to view.
Growth of DCAT Week Spurs Expansion of Annual Event’s NYC Meeting Space
ROBBINSVILLE, N.J. Due to the significant increase in attendance and opportunities for updated business meeting space, the Drug, Chemical & Associated Technologies Association (DCAT) announced...
View ArticleClik here to view.
ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for...
GENEVA & SINGAPORE Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and ASLAN Pharmaceuticals, a biotech company...
View ArticleClik here to view.
Chugai’s Emicizumab Showed Continued Benefits in Patients with Hemophilia A
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that latest data from an ongoing Japanese Phase I/II study (ACE002JP) of emicizumab was presented at the World Federation of...
View ArticleClik here to view.
Gland Pharma to be Acquired by Fosun Pharma
HYDERABAD Gland Pharma Limited (“Gland” or “The Company”), a leading Indian pure-play generic injectable pharmaceutical products company, today announced the signing of a definitive agreement under...
View ArticleClik here to view.
Acelity to Offer New Gelling Fiber Advanced Wound Dressing
SAN ANTONIO Acelity, a global advanced wound care and regenerative medicine company, announced today that BIOSORB™ Gelling Fiber Dressing is now available in the United States and has Conformité...
View ArticleClik here to view.
Astellas Launches DigiTx Partners, a Digital Health Investment Company in...
TOKYO & SAN FRANCISCO Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and DigiTx Partners LLC (CEO: David Kim, “DigiTx Partners”) announce that Astellas has launched...
View ArticleClik here to view.
武田薬品：2016年度第1四半期の連結業績について力強いスタートで年間マネジメントガイダンスを堅持
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 2016年度第1四半期（4-6月期）の力強い業績により、年間マネジメントガイダンスを堅持...
View ArticleClik here to view.
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Strong first quarter results and confidence in Management Guidance • Underlying revenue grew +9.1%, driven by a +15.3% increase...
View ArticleClik here to view.
DCAT Week规模扩大促使该年度盛会增加其纽约市会议空间
新泽西州罗宾斯维尔 (美国商业资讯)–鉴于出席人数的大幅增加和升级后商业会议空间所带来的机遇，药物、化学品和相关技术协会(DCAT)宣布，该机构将在曼哈顿中城区增设四个会场，以扩大其旗舰盛会DCAT Week（2017年3月20日-23日）的规模。DCAT Week是医药研发和生产以及相关行业领域企业的首要业务开发盛会。 DCAT...
View ArticleClik here to view.
Clik here to view.
Ligand Announces Multi-Program LTP Technology Licensing Agreement with...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion...
View ArticleClik here to view.
武田公布2016财年第一季度业绩，财年开局喜人，有信心实现管理层指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(TOKYO:4502)： 强劲的第一季度业绩，有信心实现管理层指引 • 基础营收增长+9.1%，得益于武田增长引擎（胃肠药、肿瘤药、CNS和新兴市场）+15.3%的增长。（根据报告的营收下降-2.8%，至4,340亿日元，归咎于撤资和货币影响） •...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”) Reports Interim Results for the...
LONDON Chi-Med (AIM/NASDAQ: HCM), the China-based biopharmaceutical company focused on discovering and developing targeted therapies for oncology and immunological diseases for the global market,...
View ArticleClik here to view.
Hutchison China MediTech Limited (“Chi-Med”): Change of Non-executive Directors
LONDON Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from August 1, 2016, Dr Dan Eldar has been appointed as a Non-Executive Director of Chi-Med in place...
View ArticleClik here to view.
NuGEN Technologies Announces Launch of Fusion Data Analysis Application,...
SAN CARLOS, Calif. NuGEN Technologies, Inc. today announced the availability of the Ovation Fusion Detection application, providing a data analysis tool for the Ovation Fusion Target Enrichment...
View ArticleClik here to view.
AmpliPhi Biosciences Granted Japanese Patent Covering the Use of Phage...
SAN DIEGO AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that...
View Article